Corium Intl Cmn (CORI) 5.80 $CORI
Corium International (CORI) Jumps: Stock Moves Up 6.9%
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 7:15AM CDT
Corium International, Inc. (CORI) was a big mover last session, as its shares rose almost 7% on the day.
CORI: 5.80 (-0.14), AMPH: 18.99 (-0.01)
Corium Announces Streamlined Bioequivalence Development Path for Transdermal Corplex(TM) Memantine
GlobeNewswire - Wed Aug 24, 7:00AM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced receiving favorable written feedback from the U.S. Food and Drug Administration (FDA) on the company's Pre-Investigational New Drug Application (PIND) submission for once-weekly transdermal Corplex Memantine.
CORI: 5.80 (-0.14)
Corium Reports Third Quarter Fiscal 2016 Financial Results and Recent Corporate Highlights
GlobeNewswire - Thu Aug 04, 3:03PM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the third fiscal quarter and the nine months ended June 30, 2016, and reported on recent corporate developments. Corium's fiscal year ends on September 30.
CORI: 5.80 (-0.14)
Corium to Report Third Quarter Fiscal Year 2016 Financial Results on Thursday, August 4, 2016
GlobeNewswire - Thu Jul 28, 7:00AM CDT
Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the third fiscal quarter ended June 30, 2016 on Thursday, August 4, 2016 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results and recently announced clinical and regulatory developments.
CORI: 5.80 (-0.14)
Corium Presents Full Clinical Results from Phase 1 Pharmacokinetic Study of Once-weekly Corplex(TM) Donepezil Transdermal System
GlobeNewswire - Wed Jul 27, 3:01PM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the presentation of full clinical trial results demonstrating sustained and controlled delivery of donepezil in the plasma concentrations of all subjects treated with Corium's once-weekly Corplex Donepezil patch. Consistent with topline interim data, the average plasma concentration with Corplex Donepezil was comparable to oral Aricept (donepezil hydrochloride), and indicative of bioequivalence. These pharmacokinetic results enabled Corium to select an optimized formulation for further clinical development and support an expedited development pathway for Corplex Donepezil.
CORI: 5.80 (-0.14)
Corium to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed May 25, 3:05PM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium's President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference in New York City on Wednesday, June 8, 2016 at 1:30 p.m. Eastern time.
CORI: 5.80 (-0.14)
Corium reports 2Q loss
Automated Insights - Tue May 10, 5:06PM CDT
MENLO PARK, Calif. (AP) _ Corium International Inc. (CORI) on Tuesday reported a loss of $10.5 million in its fiscal second quarter.
CORI: 5.80 (-0.14)
Corium Reports Second Quarter Fiscal 2016 Financial Results and Recent Corporate Highlights
GlobeNewswire - Tue May 10, 4:07PM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the second fiscal quarter and the six months ended March 31, 2016 and reported on recent corporate developments. Corium's fiscal year ends on September 30.
CORI: 5.80 (-0.14)
Corium International (CORI) Jumps: Stock Moves 9.5% Higher
Zacks Equity Research - Zacks Investment Research - Wed May 04, 7:15AM CDT
Corium International, Inc. (CORI) shares rose almost 10% in the last trading session.
CORI: 5.80 (-0.14), AMPH: 18.99 (-0.01)
Corium to Report Second Quarter Fiscal Year 2016 Financial Results on Tuesday, May 10, 2016
GlobeNewswire - Tue May 03, 3:06PM CDT
Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the second fiscal quarter ended March 31, 2016 on Tuesday, May 10, 2016 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results and recently announced clinical and regulatory developments.
CORI: 5.80 (-0.14)
Corium Announces Streamlined Bioequivalence Development Path for Transdermal Corplex(TM) Donepezil Following Positive Pre-IND Communication from FDA
GlobeNewswire - Mon May 02, 3:05PM CDT
Reports Positive PK Results from Clinical Study of Optimized Once-weekly Corplex Donepezil for Alzheimer's Disease
CORI: 5.80 (-0.14)
Docutech(TM) announces David Aach to join as New Executive Vice President
BusinessWire - Thu Mar 31, 8:00AM CDT
Docutech, a leading provider of compliance and documentation technology, today announced that David Aach has joined the management team. In his role, Aach will initially focus on helping to grow revenues by working closely with Docutech's industry partners and financial services clients and prospects.
CORI: 5.80 (-0.14), IBM: 159.54 (+0.66)
Corium to Present at 15th Annual Needham Healthcare Conference
GlobeNewswire - Thu Mar 31, 7:00AM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium's President and Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference in New York City on Tuesday, April 12, 2016 at 3:40 p.m. Eastern time.
CORI: 5.80 (-0.14)
Corium Announces Positive Preclinical Results with Long-acting Potent GLP-1 Analog Delivered in MicroCor(R) Transdermal Patch
GlobeNewswire - Tue Mar 29, 3:03PM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the publication of a paper in the Early Edition of the Proceedings of the National Academy of Sciences (PNAS), titled "Long-acting Potent GLP-1 Analog Delivered in Microstructure-based Transdermal Patch". The results demonstrate that the combination of MicroCor transdermal system with E6, a new GLP-1R agonist, resulted in improved peptide effectiveness by increasing plasma stability and providing sustained glucose control in a preclinical proof-of-concept study.
CORI: 5.80 (-0.14)
Corium incurs higher net loss of USD9.4m for Q1 fiscal 2016
M2 - Tue Feb 09, 3:59AM CST
Biopharmaceutical company Corium International (NasdaqGM:CORI) on Monday declared a net loss of USD9.4m (USD0.42 per share) for the first fiscal quarter ended 31 December 2015.
CORI: 5.80 (-0.14)
Corium Reports First Quarter Fiscal 2016 Financial Results
GlobeNewswire - Mon Feb 08, 3:03PM CST
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results from operations for the first fiscal quarter ended December 31, 2015. Corium's fiscal year ends on September 30.
CORI: 5.80 (-0.14)
Corium Announces Positive Topline Results From Phase 1 PK Clinical Study of Once-Weekly Transdermal Corplex(TM) Donepezil as a Potential Treatment of Alzheimer's Disease
GlobeNewswire - Wed Feb 03, 3:03PM CST
Demonstrates Sustained Delivery, Acceptable Skin Tolerability, and Pharmacokinetic Profile to Support the Feasibility of Once-Weekly Dosing
CORI: 5.80 (-0.14)
Migraine Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/tw7v3m/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Migraine Overview - Therapeutics Development - Pipeline Products for Migraine - Overview - Pipeline Products for Migraine - Comparative Analysis - Migraine - Therapeutics under Development by Companies - Migraine - Therapeutics under Investigation by Universities/Institutes - Migraine - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Migraine - Products under Development by Companies - Migraine - Products under Investigation by Universities/Institutes - Migraine - Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos S/A - Acorda Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - Alder Biopharmaceuticals Inc. - Allergan Plc - Amgen Inc. - Astellas Pharma Inc. - BioDelivery Sciences International, Inc. - Biofrontera AG - Charleston Laboratories, Inc. - CoLucid Pharmaceuticals, Inc. - Corium International, Inc. - D-Pharm Ltd. - Eli Lilly and Company - iCeutica, Inc. - Impel NeuroPharma, Inc. - Mallinckrodt Plc - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Nektar Therapeutics - Noxxon Pharma AG - Otsuka Holdings Co., Ltd. - Pantarhei Bioscience BV - Pivot Pharmaceuticals Inc - Pozen, Inc. - Promius Pharma, LLC - RedHill Biopharma Ltd. - Revance Therapeutics, Inc. - Shin Nippon Biomedical Laboratories, Ltd. - Suda Ltd - Teva Pharmaceutical Industries Limited - TheraJect, Inc. - Trevena, Inc. - Trigemina, Inc. - Vertex Pharmaceuticals Incorporated - Zosano Pharma Corporation For more information visit http://www.researchandmarkets.com/research/tw7v3m/migraine
BDSI: 2.45 (+0.01), TRVN: 6.77 (-0.01), VRTX: 94.75 (+0.24), RDHL: 14.88 (-0.09), ZSAN: 0.77 (-0.03), AMGN: 170.13 (+0.07), LLY: 77.23 (-0.52), ACOR: 24.34 (+0.26), NKTR: 18.11 (+0.26), AGN: 237.76 (+3.22), CORI: 5.80 (-0.14), ALDR: 32.54 (-0.43), CLCD: 10.25 (-0.02), MRK: 62.90 (+0.11), TEVA: 50.90 (+0.51), RVNC: 14.04 (-0.01), POZN: 5.94 (-0.43)
Corium International (CORI) Jumps: Stock Moves Up 6.9%
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 7:15AM CDT
Corium International, Inc. (CORI) was a big mover last session, as its shares rose almost 7% on the day.
CORI: 5.80 (-0.14), AMPH: 18.99 (-0.01)
Corium Announces Streamlined Bioequivalence Development Path for Transdermal Corplex(TM) Memantine
GlobeNewswire - Wed Aug 24, 7:00AM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced receiving favorable written feedback from the U.S. Food and Drug Administration (FDA) on the company's Pre-Investigational New Drug Application (PIND) submission for once-weekly transdermal Corplex Memantine.
CORI: 5.80 (-0.14)
Corium Reports Third Quarter Fiscal 2016 Financial Results and Recent Corporate Highlights
GlobeNewswire - Thu Aug 04, 3:03PM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the third fiscal quarter and the nine months ended June 30, 2016, and reported on recent corporate developments. Corium's fiscal year ends on September 30.
CORI: 5.80 (-0.14)
Corium to Report Third Quarter Fiscal Year 2016 Financial Results on Thursday, August 4, 2016
GlobeNewswire - Thu Jul 28, 7:00AM CDT
Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the third fiscal quarter ended June 30, 2016 on Thursday, August 4, 2016 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results and recently announced clinical and regulatory developments.
CORI: 5.80 (-0.14)
Corium Presents Full Clinical Results from Phase 1 Pharmacokinetic Study of Once-weekly Corplex(TM) Donepezil Transdermal System
GlobeNewswire - Wed Jul 27, 3:01PM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the presentation of full clinical trial results demonstrating sustained and controlled delivery of donepezil in the plasma concentrations of all subjects treated with Corium's once-weekly Corplex Donepezil patch. Consistent with topline interim data, the average plasma concentration with Corplex Donepezil was comparable to oral Aricept (donepezil hydrochloride), and indicative of bioequivalence. These pharmacokinetic results enabled Corium to select an optimized formulation for further clinical development and support an expedited development pathway for Corplex Donepezil.
CORI: 5.80 (-0.14)
Corium to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed May 25, 3:05PM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium's President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference in New York City on Wednesday, June 8, 2016 at 1:30 p.m. Eastern time.
CORI: 5.80 (-0.14)
Corium reports 2Q loss
Automated Insights - Tue May 10, 5:06PM CDT
MENLO PARK, Calif. (AP) _ Corium International Inc. (CORI) on Tuesday reported a loss of $10.5 million in its fiscal second quarter.
CORI: 5.80 (-0.14)
Corium Reports Second Quarter Fiscal 2016 Financial Results and Recent Corporate Highlights
GlobeNewswire - Tue May 10, 4:07PM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the second fiscal quarter and the six months ended March 31, 2016 and reported on recent corporate developments. Corium's fiscal year ends on September 30.
CORI: 5.80 (-0.14)
Corium International (CORI) Jumps: Stock Moves 9.5% Higher
Zacks Equity Research - Zacks Investment Research - Wed May 04, 7:15AM CDT
Corium International, Inc. (CORI) shares rose almost 10% in the last trading session.
CORI: 5.80 (-0.14), AMPH: 18.99 (-0.01)
Corium to Report Second Quarter Fiscal Year 2016 Financial Results on Tuesday, May 10, 2016
GlobeNewswire - Tue May 03, 3:06PM CDT
Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the second fiscal quarter ended March 31, 2016 on Tuesday, May 10, 2016 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results and recently announced clinical and regulatory developments.
CORI: 5.80 (-0.14)
Corium Announces Streamlined Bioequivalence Development Path for Transdermal Corplex(TM) Donepezil Following Positive Pre-IND Communication from FDA
GlobeNewswire - Mon May 02, 3:05PM CDT
Reports Positive PK Results from Clinical Study of Optimized Once-weekly Corplex Donepezil for Alzheimer's Disease
CORI: 5.80 (-0.14)
Docutech(TM) announces David Aach to join as New Executive Vice President
BusinessWire - Thu Mar 31, 8:00AM CDT
Docutech, a leading provider of compliance and documentation technology, today announced that David Aach has joined the management team. In his role, Aach will initially focus on helping to grow revenues by working closely with Docutech's industry partners and financial services clients and prospects.
CORI: 5.80 (-0.14), IBM: 159.54 (+0.66)
Corium to Present at 15th Annual Needham Healthcare Conference
GlobeNewswire - Thu Mar 31, 7:00AM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium's President and Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference in New York City on Tuesday, April 12, 2016 at 3:40 p.m. Eastern time.
CORI: 5.80 (-0.14)
Corium Announces Positive Preclinical Results with Long-acting Potent GLP-1 Analog Delivered in MicroCor(R) Transdermal Patch
GlobeNewswire - Tue Mar 29, 3:03PM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the publication of a paper in the Early Edition of the Proceedings of the National Academy of Sciences (PNAS), titled "Long-acting Potent GLP-1 Analog Delivered in Microstructure-based Transdermal Patch". The results demonstrate that the combination of MicroCor transdermal system with E6, a new GLP-1R agonist, resulted in improved peptide effectiveness by increasing plasma stability and providing sustained glucose control in a preclinical proof-of-concept study.
CORI: 5.80 (-0.14)
Corium incurs higher net loss of USD9.4m for Q1 fiscal 2016
M2 - Tue Feb 09, 3:59AM CST
Biopharmaceutical company Corium International (NasdaqGM:CORI) on Monday declared a net loss of USD9.4m (USD0.42 per share) for the first fiscal quarter ended 31 December 2015.
CORI: 5.80 (-0.14)
Corium Reports First Quarter Fiscal 2016 Financial Results
GlobeNewswire - Mon Feb 08, 3:03PM CST
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results from operations for the first fiscal quarter ended December 31, 2015. Corium's fiscal year ends on September 30.
CORI: 5.80 (-0.14)
Corium Announces Positive Topline Results From Phase 1 PK Clinical Study of Once-Weekly Transdermal Corplex(TM) Donepezil as a Potential Treatment of Alzheimer's Disease
GlobeNewswire - Wed Feb 03, 3:03PM CST
Demonstrates Sustained Delivery, Acceptable Skin Tolerability, and Pharmacokinetic Profile to Support the Feasibility of Once-Weekly Dosing
CORI: 5.80 (-0.14)
Migraine Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/tw7v3m/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Migraine Overview - Therapeutics Development - Pipeline Products for Migraine - Overview - Pipeline Products for Migraine - Comparative Analysis - Migraine - Therapeutics under Development by Companies - Migraine - Therapeutics under Investigation by Universities/Institutes - Migraine - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Migraine - Products under Development by Companies - Migraine - Products under Investigation by Universities/Institutes - Migraine - Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos S/A - Acorda Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - Alder Biopharmaceuticals Inc. - Allergan Plc - Amgen Inc. - Astellas Pharma Inc. - BioDelivery Sciences International, Inc. - Biofrontera AG - Charleston Laboratories, Inc. - CoLucid Pharmaceuticals, Inc. - Corium International, Inc. - D-Pharm Ltd. - Eli Lilly and Company - iCeutica, Inc. - Impel NeuroPharma, Inc. - Mallinckrodt Plc - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Nektar Therapeutics - Noxxon Pharma AG - Otsuka Holdings Co., Ltd. - Pantarhei Bioscience BV - Pivot Pharmaceuticals Inc - Pozen, Inc. - Promius Pharma, LLC - RedHill Biopharma Ltd. - Revance Therapeutics, Inc. - Shin Nippon Biomedical Laboratories, Ltd. - Suda Ltd - Teva Pharmaceutical Industries Limited - TheraJect, Inc. - Trevena, Inc. - Trigemina, Inc. - Vertex Pharmaceuticals Incorporated - Zosano Pharma Corporation For more information visit http://www.researchandmarkets.com/research/tw7v3m/migraine
BDSI: 2.45 (+0.01), TRVN: 6.77 (-0.01), VRTX: 94.75 (+0.24), RDHL: 14.88 (-0.09), ZSAN: 0.77 (-0.03), AMGN: 170.13 (+0.07), LLY: 77.23 (-0.52), ACOR: 24.34 (+0.26), NKTR: 18.11 (+0.26), AGN: 237.76 (+3.22), CORI: 5.80 (-0.14), ALDR: 32.54 (-0.43), CLCD: 10.25 (-0.02), MRK: 62.90 (+0.11), TEVA: 50.90 (+0.51), RVNC: 14.04 (-0.01), POZN: 5.94 (-0.43)
